Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas

Hepatology

Volumn 58, Issue 3, 2013, Pages 983-994

  Poté, Nicolas ^a,b   Alexandrov, Theodore ^c,d   Le Faouder, Julie ^b,e   Laouirem, Samira ^b   Léger, Thibaut ^f   Mebarki, Mouniya ^b   Belghiti, Jacques ^a   Camadro, Jean Michel ^f   Bedossa, Pierre ^a,b   Paradis, Valérie ^a,b  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c UNIVERSITY OF BREMEN   (Germany)

^d Steinbeis Innovation Center SCiLS   (Germany)

^e BICHAT HOSPITAL   (France)

^f INSTITUT JACQUES MONOD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H4; LYSINE; PROTEOME;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROVASCULAR INVASION; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR INVASION; WESTERN BLOTTING;

AGED; BIOPSY; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE MANAGEMENT; FEMALE; HISTONES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84883223403     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26433     Document Type: Article

References (36)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
3. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080-1086.
4. Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008;15:1375-1382.
5. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207.
6. Schlitt HJ, Neipp M, Weimann A, Oldhafer KJ, Schmoll E, Boeker K, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 1999;17:324-331.
7. Ho M-C, Lin J-J, Chen C-N, Chen C-C, Lee H, Yang C-Y, et al. A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach. Ann Surg Oncol 2006;13:1474-1484.
8. Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, et al. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011;55:1325-1331.
9. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem 1997;69:4751-4760.
10. Schwamborn K, Caprioli RM. Molecular imaging by mass spectrometry-looking beyond classical histology. Nat Rev Cancer 2010;10:639-646.
11. Balluff B, Rauser S, Ebert MP, Siveke JT, Höfler H, Walch A. Direct molecular tissue analysis by MALDI imaging mass spectrometry in the field of gastrointestinal disease. Gastroenterology 2012;143:544-549.e1-2.
12. Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005;65:7674-7681.
13. Meding S, Balluff B, Elsner M, Schöne C, Rauser S, Nitsche U, et al. Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol 2012;228:459-470.
14. Cazares LH, Troyer D, Mendrinos S, Lance RA, Nyalwidhe JO, Beydoun HA, et al. Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res 2009;15:5541-5551.
15. Le Faouder J, Laouirem S, Chapelle M, Albuquerque M, Belghiti J, Degos F, et al. Imaging mass spectrometry provides fingerprints for distinguishing hepatocellular carcinoma from cirrhosis. J Proteome Res 2011;10:3755-3765.
16. Lagarrigue M, Alexandrov T, Dieuset G, Perrin A, Lavigne R, Baulac S, et al. New analysis workflow for MALDI imaging mass spectrometry: application to the discovery and identification of potential markers of childhood absence epilepsy. J Proteome Res 2012;11:5453-5463.
17. Alexandrov T, Decker J, Mertens B, Deelder AM, Tollenaar RAEM, Maass P, et al. Biomarker discovery in MALDI-TOF serum protein profiles using discrete wavelet transformation. Bioinformatics 2009;25:643-649.
18. Lim K-C, Chow PK-H, Allen JC, Chia G-S, Lim M, Cheow P-C, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 2011;254:108-113.
19. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
20. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
21. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001;7:493-496.
22. Seeley EH, Caprioli RM. MALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives. Trends Biotechnol 2011;29:136-143.
23. Cai M-Y, Hou J-H, Rao H-L, Luo R-Z, Li M, Pei X-Q, et al. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med 2011;17:12-20.
24. Fan DN-Y, Tsang FH-C, Tam AH-K, Au SL-K, Wong CC-L, Wei L, et al. Histone lysine methyltransferase, SUV39H1, promotes HCC progression and is negatively regulated by microRNA-125b. Hepatology 2012;57:637-647.
25. He C, Xu J, Zhang J, Xie D, Ye H, Xiao Z, et al. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol 2012;43:1425-1435.
26. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705.
27. Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer. Part I. Covalent histone modifications. Trends Mol Med 2007;13:363-372.
28. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-1266.
29. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009;69:3802-3809.
30. Shogren-Knaak M, Ishii H, Sun J-M, Pazin MJ, Davie JR, Peterson CL. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 2006;311:844-847.
31. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
32. Gupta A, Guerin-Peyrou TG, Sharma GG, Park C, Agarwal M, Ganju RK, et al. The mammalian ortholog of Drosophila MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Mol Cell Biol 2008;28:397-409.
33. Schotta G, Sengupta R, Kubicek S, Malin S, Kauer M, Callén E, et al. A chromatin-wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse. Genes Dev 2008;22:2048-2061.
34. Botuyan MV, Lee J, Ward IM, Kim J-E, Thompson JR, Chen J, et al. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell 2006;127:1361-1373.
35. Kuo AJ, Song J, Cheung P, Ishibe-Murakami S, Yamazoe S, Chen JK, et al. The BAH domain of ORC1 links H4K20me2 to DNA replication licensing and Meier-Gorlin syndrome. Nature 2012;484:115-119.
36. Pawlik TM, Delman KA, Vauthey J-N, Nagorney DM, Ng IO-L, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086-1092.